Comparative analysis between ankylosing spondylitis and axial psoriatic arthritis patients

被引:6
|
作者
Abdelaziz, Marwa Mahmoud [1 ]
Ismail, Nadia [1 ]
Gamal, Aya M. [1 ]
Lafy, Raghda [2 ]
El-Adly, Wael [3 ]
机构
[1] Assiut Univ, Rheumatol & Rehabil Dept, Fac Med, Assiut, Egypt
[2] Assiut Univ, Students Hosp, Rheumatol & Rehabil Dept, Assiut, Egypt
[3] Assiut Univ, Dept Orthoped Surg, Fac Med, Assiut, Egypt
来源
EGYPTIAN RHEUMATOLOGIST | 2022年 / 44卷 / 01期
关键词
Ankylosing spondylitis; Psoriatic arthritis; Axial spondyloarthritis; Comparative analysis; CLASSIFICATION CRITERIA; SPINAL MOBILITY; SPONDYLOARTHRITIS; DISEASE; EPIDEMIOLOGY;
D O I
10.1016/j.ejr.2021.07.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim of the work: To compare clinical aspects, disease activity, spinal mobility, and radiographic findings between ankylosing spondylitis (AS) and axial psoriatic arthritis (axPsA) patients Patients and methods: Fifty-eight AS and 42 axPsA patients were enrolled. Patients were assessed by clinical examination, spinal mobility measurements, and conventional radiographs of the sacroiliac joints, lumbosacral and cervical spines. Bath. AS Metrology Index (BASMI) and modified Stoke AS Spinal Score (mSASSS) were measured. Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index score and AS Disease Activity Score (ASDAS) were assessed. Results: The mean age of AS and AxPsA patients were comparable (37.2 +/- 11.2 years vs 39.6 +/- 13.3 years;p = 0.33) and male:female was 2.63 vs 0.24:1 (p < 0.0001). Inflammatory back pain (IBP) was higher in AS (93.1%) than axPsA (76.2%). Peripheral arthritis was higher in axPsA (85.7%) than in AS (39.7%). Dactylitis and nail dystrophy were present only in axPsA (33.3% and 28.6% respectively) while uveitis was more common in AS (60.3%vs 28.6%;p = 0.12). SPARCC score was higher in axPsA (p = 0.12).The median BASMI was higher in AS (2.1) than axPsA (1.2)(p = 0.07). The mSASSS was similar (AS:19.6 +/- 4.7;6-40 and axPsA:14.4 +/- 2.1;0-32)(p = 0.23). 63.8% of AS patients had grade 3 sacroiliitis while 61.9% of axPsA had grade 2. 75.9% of AS had high ASDAS while 33.3% of axPsA patients had very high activity (p = 0.039). Conclusions: AS patients were more likely to be males, smoked, higher IBP, lower peripheral arthritis, more uveitis, higher limitation in spinal mobility measurements, more spinal deformities, and severe radiographic involvement with nearly equal disease activity as in axPsA patients. (c) 2021 THE AUTHORS. Publishing services by ELSEVIER B.V. on behalf of The Egyptian Society of Rheumatic Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页码:25 / 29
页数:5
相关论文
共 50 条
  • [41] RENAL AFFECTION IN PATIENTS WITH ANKYLOSING-SPONDYLITIS AND PSORIATIC-ARTHRITIS
    OMDAL, R
    HUSBY, G
    CLINICAL RHEUMATOLOGY, 1987, 6 (01) : 74 - 79
  • [42] DIFFERENCES IN PROINFLAMMATORY AND LIPID PROFILE BETWEEN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS
    Bonek, K.
    Kuca-Warnawin, E.
    Ciechomska, M.
    Gluszko, P.
    Kontny, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 822 - 822
  • [43] PATTERNS OF BIOLOGICS USE IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS PATIENTS IN KOREA
    Kim, H.
    Kim, J.
    Shin, K.
    Ko, S.
    VALUE IN HEALTH, 2017, 20 (09) : A541 - A541
  • [44] CURRENT NEEDS, IMPACT AND PERSPECTIVE OF PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS
    Plazuelo-Ramos, P.
    Loza, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 263 - 264
  • [45] PREVALENCE AND DIFFERENCES OF THE METABOLIC SYNDROME IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Nemes, D.
    Amaricai, E.
    Catan, L.
    Dragoi, M.
    Popa, D.
    Puenea, G.
    Andrei, D.
    Balacescu, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 951 - 951
  • [46] COMPARATIVE DRUG SURVIVAL OF TNF INHIBITORS AND SECUKINUMAB IN BIOLOGIC NAIVE PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS
    Cheila, M.
    Douglas, K.
    Koutsianas, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 723 - 724
  • [47] GolimumabIn the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Vicki Oldfield
    Greg L. Plosker
    BioDrugs, 2009, 23 : 125 - 135
  • [48] Golimumab In the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    Oldfield, Vicki
    Plosker, Greg L.
    BIODRUGS, 2009, 23 (02) : 125 - 135
  • [49] Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
    George, Michael D.
    Baker, Joshua F.
    Ogdie, Alexis
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [50] Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
    Poddubnyy, Denis
    Rudwaleit, Martin
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (04) : 655 - 673